title: Systemic treatment of patients with metachronous peritoneal carcinomatosis of colorectal origin.
abstract: Combining chemotherapy and targeted therapies has resulted in an enhanced survival in metastatic colorectal cancer (mCRC) patients. However, the result of this palliative treatment in patients with metachronous peritoneal carcinomatosis (PC) remains unknown. The current population-based study aims to investigate the use and effect of palliative systemic treatment in patients with metachronous PC of colorectal origin. Data on metachronous PC were collected between 2010 and 2011 for all patients who were diagnosed with M0 colorectal cancer between 2003 and 2008 in the Dutch Eindhoven Cancer Registry. Patient demographics and detailed data on chemotherapeutic treatment were collected and compared. Ninety-two patients with metachronous PC received chemotherapy in a palliative setting compared to 94 patients without treatment. In 36 patients, Bevacizumab was added to the treatment (39%). Overall survival was 3.4, 13, and 20.3 months in the no treatment, systemic treatment and systemic treatment + Bevacizumab respectively (P < 0.001). Male gender was a positive predictor and right sided primary tumor location a negative predictor of receiving bevacizumab. Approximately 40% of patients with metachronous PC received bevacizumab in addition to chemotherapy. Treatment with systemic chemotherapy in combination with bevacizumab may increase survival in a patients with metachronous colorectal PC.
authors.affiliation: Department of Surgery, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, the Netherlands.|Department of research, Netherlands Comprehensive Cancer Organization (IKNL), postbus 213, 5600 AE Eindhoven, The Netherlands.
authors.forename: T R
authors.initials: TR
authors.lastname: van Oudheusden
authors.affiliation: Department of research, Netherlands Comprehensive Cancer Organization (IKNL), postbus 213, 5600 AE Eindhoven, The Netherlands.|Department of Oncology, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, the Netherlands.
authors.forename: L G
authors.initials: LG
authors.lastname: Razenberg
authors.affiliation: Department of research, Netherlands Comprehensive Cancer Organization (IKNL), postbus 213, 5600 AE Eindhoven, The Netherlands.
authors.forename: Y R
authors.initials: YR
authors.lastname: van Gestel
authors.affiliation: Department of Oncology, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, the Netherlands.
authors.forename: G J
authors.initials: GJ
authors.lastname: Creemers
authors.affiliation: Department of research, Netherlands Comprehensive Cancer Organization (IKNL), postbus 213, 5600 AE Eindhoven, The Netherlands.|Department of Public Health, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.
authors.forename: V E
authors.initials: VE
authors.lastname: Lemmens
authors.affiliation: Department of Surgery, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, the Netherlands.
authors.forename: I H
authors.initials: IH
authors.lastname: de Hingh
mesh_terms: D000368:Aged; D000068258:Bevacizumab / Q000008:administration & dosage; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D016609:Neoplasms, Second Primary / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D010166:Palliative Care; D012727:Sex Characteristics
chemical_list: D000068258:Bevacizumab